The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Abstract
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is frequently over‐expressed in human cancers and is associated with tumorigenesis, and increased tumor proliferation and progression. Also found in breast tumors with high levels is B‐Myb, a transcription factor whose expression is activated by E2F1/3 at the late G 1 phase and the level is sustained through the S phase. Recent reports suggest a casual correlation between EGFR and B‐Myb expression in primary breast carcinomas. However, the mechanism for such co‐expression remains un‐investigated. Here, we report that EGFR is important for B‐Myb expression and the underlying mechanism involves cooperated effects from EGFR and E2F1. EGF stimulation and forced expression of EGFR significantly increase B‐Myb gene activity and such increase occurs in the G 1 phase. EGF‐induced B‐Myb expression was not significantly suppressed following inhibition of PI‐3K and ERK, two major EGFR downstream pathways. In contrast, we observed EGF‐induced in vivo association of nuclear EGFR to the B‐Myb promoter and the association is only detected at the G 1/S phase and is abolished by EGFR kinase inhibitor. As EGFR lacks DNA‐binding domain but contains transactivational activity and E2F1 activates B‐Myb expression in the G 1/S phase, we further reasoned that nuclear EGFR might cooperate with E2F1 leading to activation of B‐Myb. Indeed, we found that EGFR co‐immunoprecipitated with E2F1 in an EGF‐dependent manner and that EGF activated in vivo binding of E2F1 to the B‐Myb promoter. Consistently, forced expression of both EGFR and E2F1 in EGFR‐null CHO cells greatly enhanced B‐Myb promoter activity, compared to the vector control and expression of EGFR or E2F1 alone. Promoter mutagenesis studies showed that EGF‐induced activation of B‐Myb promoter required both E2F and EGFR target sites. In summary, our data suggest that deregulated EGFR signaling pathway facilitate tumor cell proliferation partly via EGFR interaction with E2F1 and subsequent activation of B‐Myb gene expression. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophosphorylation sites on the epidermal growth factor receptor
Downward, J., Parker, P., & Waterfield, M. D. (1984) · Nature · doi:10.1038/311483a0 · Cited by 704
Cited by
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
Zhou, H., S. Beevers, C., & Huang, S. (2011) · Current Drug Targets · doi:10.2174/138945011794815356 · Cited by 715
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Protein localization in disease and therapy
Hung, M.-C., & Link, W. (2011) · Journal of Cell Science · doi:10.1242/jcs.089110 · Cited by 431
Self-citationMaier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Self-citationMolecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Self-citationFrau, M., Ladu, S., Calvisi, D. F., Simile, M. M., Bonelli, P., Daino, L., Tomasi, M. L., Seddaiu, M. A., Feo, F., & Pascale, R. M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.031 · Cited by 60
Metadata
- Authors
- Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2005-11-20
- Volume
- 45
- Issue
- 1
- Pages
- 10-17
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2051570504
- Cited by
- 188
- References
- 1
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.